Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

OCEA

Ocean Biomedical Inc.

Dec 08 • 04:00PM ET

0.6054

Dollar change +0.0444
Percentage change 7.91	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.25	Insider Own	74.86%	Shs Outstand	10.60M	Perf Week	-26.56%
Market Cap	20.59M	Forward P/E	-	EPS next Y	-0.89	Insider Trans	0.00%	Shs Float	8.55M	Perf Month	-63.75%
Income	-81.04M	PEG	-	EPS next Q	-0.19	Inst Own	18.36%	Short Float / Ratio	6.04% / 1.83	Perf Quarter	-85.52%
Sales	0.00M	P/S	-	EPS this Y	-498.06%	Inst Trans	2.91%	Short Interest	0.52M	Perf Half Y	-89.09%
Book/sh	-0.25	P/B	-	EPS next Y	71.10%	ROA	-125.17%	Target Price	18.50	Perf Year	-94.09%
Cash/sh	0.06	P/C	9.53	EPS next 5Y	-	ROE	-167.94%	52W Range	0.53 - 26.60	Perf YTD	-94.18%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-97.72%	Beta	-0.28
Dividend %	-	Quick Ratio	0.08	Sales past 5Y	0.00%	Gross Margin	-	52W Low	14.01%	ATR	0.13
Employees	9	Current Ratio	0.08	Sales Q/Q	-	Oper. Margin	0.00%	RSI (14)	16.78	Volatility	19.42% 13.06%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	-3415.71%	Profit Margin	-	Rel Volume	0.84	Prev Close	0.56
Shortable	Yes	LT Debt/Eq	-	Earnings	-	Payout	-	Avg Volume	282.30K	Price	0.61
Recom	1.00	SMA20	-41.73%	SMA50	-64.49%	SMA200	-86.97%	Volume	238,322	Change	7.91%

Dec-05-23 09:45AM	EXCLUSIVE: Ocean Biomedical Announces Publication of Breast Cancer Research On New Tumor Suppression Pathway for Proprietary Antibody (Benzinga)
08:15AM	Ocean Biomedical, Inc. Announces Publication of Groundbreaking Breast Cancer Research Uncovering a New Tumor Suppression Pathway for Its Proprietary Anti-Chi3L1 Antibody (GlobeNewswire)
Nov-29-23 05:41PM	Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q (GlobeNewswire) -8.95%
Nov-14-23 08:01AM	Ocean Biomedical (NASDAQ: OCEA) Announces Positive Preclinical Oncology Data for VRON-0300, Presented at SITC 2023 Annual Meeting, and Clinical Updates by 50/50 Joint Venture Partner Virion Therapeutics (GlobeNewswire) -15.36%
Nov-01-23 07:00AM	Presenting on the Emerging Growth Conference 64 Day 2 on November 2 Register Now (GlobeNewswire)
07:00AM	Loading…
Oct-31-23 07:00AM	Presenting on the Emerging Growth Conference 64 Day 1 on November 1 Register Now (GlobeNewswire)
Oct-26-23 06:30AM	EXCLUSIVE: Ocean Biomedical's JV Partner Virion Therapeutics Dosed First Patients In Novel Immunotherapy Study For Chronic Hepatitis B (Benzinga)
05:30AM	Virion Therapeutics and Joint Venture Partner, Ocean Biomedical (NASDAQ: OCEA), Announce First Patients Dosed with Novel Immunotherapy Evaluating a Functional Cure for Chronic Hepatitis B Virus Infection (PR Newswire)
05:30AM	Ocean Biomedical (NASDAQ: OCEA) Announces First Patients Dosed by Joint Venture Partner Virion Therapeutics in Phase 1b Study of Novel Immunotherapy for Chronic Hepatitis B Virus Infection (GlobeNewswire)
Oct-24-23 06:30AM	Ocean Biomedical (NASDAQ: OCEA) Announces $1 Million Falk Award for Malaria Drug Candidate Addressing Evolving Resistance to Artemisinin-Based Therapeutics to Chief Scientist Dr. Jonathan Kurtis (GlobeNewswire)
Oct-17-23 08:01AM	Ocean Biomedical (NASDAQ: OCEA) Announces Enrollment of Patients for Phase 1b Study for Chronic Hepatitis B Treatment in 50-50 Joint Venture with Virion Therapeutics (GlobeNewswire)
Oct-12-23 08:01AM	Virion Therapeutics and Ocean Biomedical form joint venture supporting multi-national, first-in-humans clinical chronic hepatitis B study: now enrolling, with goal of a functional cure for a disease affecting 300+ million patients worldwide (PR Newswire)
08:01AM	Ocean Biomedical and Virion Therapeutics Form Joint Venture Supporting Multi-National, First-In-Humans Clinical Chronic Hepatitis B Study: Now Enrolling, With Goal of a Functional Cure for a Disease Affecting 300+ Million Patients Worldwide (GlobeNewswire)
Oct-11-23 08:26AM	3 Growth Stocks To Make You The Millionaire Next Door: October Edition (InvestorPlace) -8.97%
Oct-04-23 04:56PM	Updated: Ocean Biomedical Announces Non-Dilutive Amendment to Existing Agreement with Polar Multi-Strategy Master Fund (GlobeNewswire) -14.60%
08:01AM	Loading…
08:01AM	Ocean Biomedical Announces Loan Commitment from Largest Stockholder; Up to $10 Million (GlobeNewswire)
Oct-03-23 02:30PM	Ocean Biomedical Announces Non-Dilutive Amendment to Existing Agreement with a Key Financing Partner (GlobeNewswire) -21.71%
08:01AM	Ocean Biomedical Announces Newly Published Findings Demonstrating Ability to Restore Treatment Sensitivity to AstraZeneca's Leading Lung Cancer Drug After Resistance Has Formed, and Enhanced Tumor Suppression in EGFR-Mutation Lung Cancers (GlobeNewswire)
Sep-14-23 08:01AM	Ocean Biomedical (NASDAQ: OCEA) Will Host an R&D Update Today on Malaria, and Fibrosis Programs with Scientific Co-founders Jack A. Elias, MD, and Jonathan Kurtis, MD PhD. (GlobeNewswire)
Aug-29-23 09:30AM	EXCLUSIVE: Ocean Biomedical Announces New Patent For Fibrosis Candidate Catering To One Of Leading Death Causes In US (Benzinga)
08:01AM	Ocean Biomedical (NASDAQ: OCEA) Announces New Patent for Anti-Fibrosis Discovery with Allowance in Alcoholic Liver Disease and Multiple Fibrotic Conditions, Leading Causes of Death in the U.S. (GlobeNewswire)
Aug-10-23 09:30AM	EXCLUSIVE: Ocean Biomedical Unveils Comprehensive Updates On Its Cancer, Malaria, Fibrosis Programs (Benzinga)
08:01AM	Ocean Biomedical (NASDAQ: OCEA) Provides Latest Updates on its Broad Programs in Malaria, Fibrosis, and Multiple Cancers (GlobeNewswire)
Aug-09-23 08:31AM	Ocean Biomedical (NASDAQ: OCEA) Share Price Target Now Averaging $18.21, Based on Research and Development Progress in Three Promising Programs Generating Novel Treatment Candidates for Cancer, Malaria, and Fibrosis. (GlobeNewswire)
Aug-01-23 08:01AM	Ocean Biomedical, Inc. (NASDAQ: OCEA) Celebrates 95% Lung Cancer Tumor Reduction Results on World Lung Cancer Day (GlobeNewswire)
Jul-11-23 08:01AM	Ocean Biomedicals (NASDAQ: OCEA) mRNA-based Vaccine Candidate Generates Over 90% Killing of Malaria Parasites in Non-human Primates, Demonstrating Broad Potential for Oceans Program to Address Global and Emerging U.S. Malaria Challenges (GlobeNewswire) -5.42%
Jun-27-23 08:01AM	Ocean Biomedical, Inc. Joins the Russell 2000® Index (GlobeNewswire) -9.77%
Jun-26-23 08:01AM	Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces U.S. Patent Issued for Bispecific Cancer Immunotherapy Treatment With Demonstrated Killing of Tumor Cells in Lung Cancer, Brain Cancer (Glioblastoma), and Metastatic Melanoma. (GlobeNewswire) -5.00%
Jun-23-23 08:01AM	Ocean Biomedical (NASDAQ: OCEA) Extends Patent Rights for Breakthrough Idiopathic Pulmonary Fibrosis Discovery To Europe (GlobeNewswire)
Jun-21-23 08:01AM	Ocean Biomedical (NASDAQ: OCEA) Announces Share Price Target Increase to $17.63 by Fundamental Research Corp. on Positive Results from Independent Study Showing Glioblastoma Tumor Suppression, Received Patents, and Recent Financing (GlobeNewswire) +27.26%
08:00AM	Loading…
Jun-13-23 08:00AM	Sidoti Events, LLC's Virtual June Small-Cap Conference (ACCESSWIRE)
Jun-08-23 08:01AM	Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Malaria Vaccine Patent Granted in Brazil, the 25th Patent Allowance for Programs in Infectious Disease, Cancer and Fibrosis (GlobeNewswire)
Jun-01-23 08:01AM	Ocean Biomedical (NASDAQ: OCEA) Announces Initiation of Coverage by Taglich Brothers with a Share Price Target of $20. (GlobeNewswire) +7.92%
May-25-23 08:01AM	Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Addition to the Russell 2000® Index (GlobeNewswire) +8.60%
May-23-23 08:01AM	Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Award for Novel Cancer Immunotherapy Treatment, Granted for Prostate Cancer, Colon Cancer, Ovarian Cancer, Kidney Cancer, Breast Cancer, Glioblastoma, Melanoma, and Lung Cancer. (GlobeNewswire) +28.14%
May-16-23 12:00PM	Ocean Biomedical Raises $25M Via Convertible Note Facility (Benzinga)
08:01AM	Ocean Biomedical, Inc. Enters into a $25 Million Convertible Note Facility (GlobeNewswire)
May-01-23 08:01AM	Ocean Biomedical (NASDAQ: OCEA) Announces 70% Increase in Price Target by EF Hutton from $10 to $17 on New Glioblastoma Results Validating Profound Tumor Suppression with Anti-Chi3L1 Antibody (GlobeNewswire)
Apr-27-23 04:53PM	Ocean Biomedical Shows More Evidence of Anti-Chi3L1 Antibody Suppressing Cancer (Exec Edge) +5.26%
09:30AM	EXCLUSIVE: Ocean Biomedical Highlights New Results From Anti-Cancer Antibody Validating Tumor Suppression In Animal Models With Brain Tumor (Benzinga)
08:01AM	Ocean Biomedical (NASDAQ: OCEA) Announces New Glioblastoma Results Validating Profound Tumor Suppression with Anti-Chi3L1 Antibody (GlobeNewswire)
Apr-25-23 09:30AM	EXCLUSIVE: Ocean Biomedical's Co-Founder Outlines Detailed Data From Malaria Vaccine At Conference (Benzinga)
08:01AM	Ocean Biomedical (NASDAQ: OCEA) on World Malaria Day Announces Sharing of New Malaria Vaccine Paradigm at PATH Malaria Research Retreat in Washington, DC, by Scientific Co-founder Dr. Jonathan Kurtis (GlobeNewswire)
Apr-20-23 09:30AM	EXCLUSIVE: Ocean Biomedical's Co-Founder Jack Elias To Receive US Patent For Lung Fibrosis Therapeutics (Benzinga) +9.42%
08:01AM	Ocean Biomedical (NASDAQ: OCEA) Announces Notice of Allowance for U.S. Patent Application for Breakthrough Pulmonary Fibrosis Treatments Issued to Scientific Co-founder Dr. Jack A. Elias. (GlobeNewswire)
Apr-17-23 09:30AM	EXCLUSIVE: Ocean Biomedical Bags $134M Backing For Innovative Research and IND Fillings (Benzinga)
08:01AM	$134 Million in Financial Backing for Innovative Research and IND Fillings Announced by Ocean Biomedical (NASDAQ: OCEA); Provides Latest Updates on Advancement of Platform, Novel Discoveries in Malaria, Pulmonary Fibrosis and Oncology (GlobeNewswire)
Apr-13-23 09:30AM	EXCLUSIVE: Ocean Biomedical's Co-Founder Expects To Receive US Patent Covering Malaria Therapeutics (Benzinga) +49.89%
08:01AM	Ocean Biomedical (NASDAQ: OCEA) Announces Notice of Allowance for U.S. Patent Application for Developing Whole New Class of Malaria Therapeutics Issued to Scientific Co-founder Dr. Jonathan Kurtis (GlobeNewswire)
Apr-06-23 08:01AM	Ocean Biomedical (NASDAQ: OCEA) Will Target Pulmonary Fibrosis Discoveries as Novel Treatments of Hermansky-Pudlak Syndrome (GlobeNewswire)
Apr-03-23 06:15AM	7 Cheap Stocks That Are Worth Your Attention (InvestorPlace) -19.28%
Mar-21-23 08:01AM	Ocean Biomedical (NASDAQ: OCEA) Details Novel Malaria Therapeutic Discoveries at the NIH Laboratory of Malaria Vaccinology and Immunology on PfGARPs Potential as a Highly Effective Vaccine Target and Therapeutic Candidate to Treat Malaria (GlobeNewswire)
Mar-16-23 08:01AM	Ocean Biomedical (NASDAQ: OCEA) Announces Initiation of Equity Analyst Coverage by Fundamental Research Corp. with a Buy Recommendation (GlobeNewswire) +6.53%
Mar-14-23 08:01AM	Ocean Biomedical (NASDAQ: OCEA) Announces Initiation of Equity Analyst Coverage by EF Hutton with a Buy Recommendation (GlobeNewswire) -11.58%
Mar-09-23 08:01AM	Ocean Biomedical (NASDAQ: OCEA) Shares Detailed Research Data on Anti-Tumor Pathway Discoveries and Their Potential for Treatment of Non-Small Cell Lung Cancer, Metastatic Melanoma, and Glioblastoma by Scientific Co-founder (GlobeNewswire) +125.16%
Feb-28-23 08:01AM	Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Award of New Patent to Scientific Co-Founder Dr. Jake Kurtis for Novel Malaria Vaccine Target (GlobeNewswire) -14.35%
Feb-23-23 02:45PM	Speculative Startups Swing Wildly After Closing SPAC Deals (The Wall Street Journal) +124.53%
08:01AM	Ocean Biomedical (NASDAQ: OCEA) Celebrates Discovery of Bispecific Antibodies and Immune Checkpoint Inhibitors That Kill Glioblastoma Cells and Melanoma Cells, and Block the Metastasis of Malignant Melanoma Cells to the Lung by Over 90% (GlobeNewswire)
Feb-16-23 08:01AM	Ocean Biomedical to Ring The Nasdaq Stock Market Opening Bell (GlobeNewswire) -10.17%
Feb-15-23 11:32AM	Ocean Biomedical Debuts as Publicly Traded Company (Exec Edge) -39.46%
08:01AM	Ocean Biomedical Debuts as Publicly Traded Company Focused on Accelerating the Commercialization of Innovative Assets from Research Universities and Medical Centers (GlobeNewswire)
Feb-09-23 09:15AM	Ocean Biomedical and Aesther Healthcare Acquisition Corp. Announce the Award of New Patents for Novel Monospecific and Bispecific Antibodies that Suppress Multiple Cancer Types (GlobeNewswire)

Ocean Biomedical, Inc. is a biopharmaceutical company. It engages in the business of discovering and developing therapeutic products in oncology, fibrosis, infectious diseases and inflammation. The company was founded by Chirinjeev Kathuria in June 2021 and is headquartered in Providence, RI.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

OCEA

Ocean Biomedical Inc.

Upgrade your FINVIZ experience